

# QED Bioscience Inc.

ADVANCED RESEARCH TECHNOLOGIES

## Anti-DRAK2 (CT) Antibody

### ORDERING INFORMATION

**Catalog No.:** 2149

**Size:** 100 ug IgG in PBS, pH 7.4, purified by immunoaffinity chroma-tography.

### BACKGROUND

Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 for DAP kinase –related apoptosis-inducing protein kinases. DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases which mediate apoptosis through their catalytic activities. DRAK2 is located in cell nuclei, and the mRNA for DRAK2 is ubiquitously expressed in human tissues.

### SPECIFICATION SUMMARY

**Antigen:** Peptide corresponding to aa 351-365 of human DRAK2.

**Host Species:** Rabbit

**Stabilizers:** None

**Preservatives:** 0.02% sodium azide.

### SPECIFICITY

This antibody recognizes human DRAK2 (45 kD). No cross-reactivity with DRAK1, DAP or ZIP kinases.

### APPLICATIONS

*Immunoblotting* : use at 1:500-1:1,000 dilution.

*Positive control*: Whole cell lysate from Jurkat cells.

### DILUTION INSTRUCTIONS

Dilute in PBS or medium which is identical to that used in the assay system.

### STORAGE AND STABILITY

This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.

*For in vitro investigational use only. Not for use in therapeutic or diagnostic procedures.*